Conference Coverage

Host: Matt Birnholz, MD

This program was recorded at the American Academy of Allergy, Asthma & Immunology (AAAAI) Conference in Atlanta, Georgia and provides perspectives from key opinion leaders in the fields of allergy, asthma, and immunology. Faculty discuss the 50-year anniversary of the discovery of IgE, including the history behind this groundbreaking discovery and current clinical applications. Faculty will also discuss the latest allergy guideline updates, such as the Peanut Addendum to the NIH Food Guidelines and the newly issued Stinging Insect Practice Parameter. Faculty: Amal H. Assa'ad, MDAssociate Director, Division of Allergy and ImmunologyDirector of Clinical Services, Division of Allergy and ImmunologyAcademic AffiliationsProfessor, UC Department of PediatricsCincinnati Children’s HospitalCincinnati, OH Sally Joo Bailey, MDAssistant Professor, Division of Allergy & ImmunologyGeorgetown University HospitalWashington, DC Magnus Borres, MD, MPH Medical Director Thermo Fisher Scientific Practicing Allergist Uppsala, Sweden Vivian P. Hernandez-Trujillo, MDDirector, Division of Allergy and ImmunologyNicklaus Children’s HospitalPSA Chief, Section of Allergy and ImmunologyMiami, FL Paolo Matricardi, MD Department of Pediatric Pneumology and Immunology Charité Medical University Berlin, Germany Thomas Platts-Mills, MD Professor of Medicine and Microbiology Allergy and Clinical Immunology University of Virginia Charlottesville, VA Jay M. Portnoy, MD Division Director, Allergy/Asthma/Immunology Professor of Pediatrics University of Missouri-Kansas City School of Medicine ...

Host: Jennifer Caudle, DO

Guest: Edward B. Garon, MD, MS

Based on CDC data, lung cancer represents 13% of all cancers diagnosed worldwide, and 19% of all cancer deaths. With almost 225,000 cases and more than 158,000 deaths anticipated in 2016 in the United States alone, lung cancer is the leading cause of cancer-associated mortality. Non-small cell lung cancer represents approximately 85% of those cases, which makes the need to better identify and treat this disease a critical need. Join us as Dr. Caudle and Dr. Garon review data on non-small cell lung cancer presented at the 17th annual World Conference on Lung Cancer held in Vienna, Austria.

Guest: Matt T. Rosenberg, MD

Thirty-three million people in the United States suffer from overactive bladder but most people will not discuss it. Join Dr. Rosenberg as he discusses OAB, the adverse consequences and burden of this disease, barriers to effective patient-physician communication, and available treatment options. He will also discuss barriers to patient adherence and how such barriers may be effectively addressed. This presentation was recorded live at From Guideline to Practice: Managing Challenging Cases in Primary Care in New York, NY in September 2016.

Host: Barnett Mennen, MD

Guest: Michael Postow, MD

Immunotherapy, notably overcoming checkpoint inhibition, has become an integral part of treatment for melanoma, if not a growing list of other cancers. In this activity, Dr. Michael Postow discusses major updates on the use of immunotherapy in melanoma as presented at the 13th International Congress of the Society for Melanoma Research that took place recently in Boston, Massachusetts. Topics include the general mechanistic principles behind immune checkpoint blockade in the treatment of metastatic melanoma; the current landscape of immune checkpoint inhibitors; and considerations for single agent vs. combination immunotherapy. Additionally, Dr. Postow will address the current value of immunotherapy biomarkers in patient selection and the independent and/or combined roles of immunotherapy and targeted therapy in the treatment of melanoma.

Host: Matt Birnholz, MD

Guest: Edward S. Kim, MD, FACP

Lung cancer is the leading cause of cancer-associated mortality, with almost 225,000 new cases and over 158,000 deaths estimated in 2016 in the United States alone. Non-small cell lung cancer (NSCLC) represents approximately 85% of those cases. Join us as Dr. Birnholz and Dr. Kim review the data presented at the 2016 annual ESMO conference and discuss the continued rise of anti-PD-1 therapy in the treatment of NSCLC. Since the recording of this interview, pembrolizumab was approved by the FDA on October 24, 2016 for use in Non-small Cell Lung Cancer.

Host: Jennifer Caudle, DO

Guest: Tanguy Seiwert, MD

The immunotherapeutic blockade of checkpoint inhibition that has resulted in stellar improvements in patient outcomes in melanoma and non-small cell lung cancer is now a likelihood for patients with head and neck cancer. Join us as Dr. Tanguy Seiwert discusses the mechanistic basis of checkpoint inhibition and the clinical data demonstrating the efficacy of anti-PD-1 agents in patients with head and neck cancer. Also discussed is the potential value of synergism between anti-checkpoint immunotherapy and current standards of care in head and neck cancer, as well as the growing relevance of biomarkers in identifying patients who will most benefit from immunotherapy.

Guest: Lawrence Sherman

What happens when you suddenly become a patient and are faced with a life-threatening illness? How do the interprofessional members of the medical team work together to help you recover as safely and quickly as possible?

From the Villanovans in Healthcare Speaker Event, join Lawrence Sherman, Senior Vice President of TOPEC Global, as he talks about innovative and collaborative interprofessional approaches to care stemming from lessons learned through his own experience as an educator-turned patient.

Host: Renée Simone Yolanda Allen, MD, MHSc., FACOG

Guest: Robert Z. Orlowski, MD, PhD

Guest: Paul G. Richardson, MD

With a steadily growing list of therapeutic agents for the treatment of patients with multiple myeloma (MM), hematologist-oncologists are equipped with more therapeutic options in the frontline and salvage settings than ever before. However, this progress brings new challenges. The increasing number of therapeutic agents, the underlying heterogeneity of the disease, and the diversity of the patient population are all factors that make patient management more complex. To help hematologist-oncologists improve their ability to incorporate the most up-to-date clinical evidence when assessing and treating patients with MM this activity will highlight the latest clinical and scientific data on MM presented at the American Society of Hematology 2015 Annual Meeting. Furthermore, the activity will provide learners with expert faculty insights and analysis of the clinical implications of these data on treating and managing patients with MM. FacultyPaul G. Richardson, MD—Program ChairR. J. Corman Professor of MedicineHarvard Medical SchoolClinical Program Leader and DirectorJerome Lipper Multiple Myeloma CenterDana-Farber Cancer InstituteBoston, Massachusetts Robert Z. Orlowski, MD, PhDChairman, Ad InterimDirector of MyelomaDepartment of Lymphoma/MyelomaProfessor, Experimental TherapeuticsDivision of Cancer MedicineUniversity of Texas MD Anderson Cancer CenterHouston, Texas

Host: Anthony Alessi, MD

Guest: Keith Flaherty, MD

The American Society of Clinical Oncology (ASCO) held its 2015 annual congress to highlight and present new data on some of the latest and most exciting discoveries in cancer research. This year’s meeting theme is – “Illumination & Innovation: Transforming Data into Learning.” Join us as Dr. Keith Flaherty, who attended ASCO 2015, gives us an update on some of the exciting data presented on the emerging potential of immunotherapeutic approaches in melanoma.

Host: Alicia A. Sutton

Guest: Linda Gracie-King, MS

From conferences to interactive on demand education, the field of continuing medical education (CME) is constantly evolving. Traditionally the preferred form of CME is live and in person, but as time goes on CME providers continue to improve their on demand CME services.

Join host, Alicia Sutton, and guest, Linda Gracie-King, MS, Managing Partner at AXIS Medical Education, on the floor of the Alliance for Continuing Education in Health Professions annual industry summit meeting in Philadelphia, PA. They discuss the future of on demand continuing medical education, with special emphasis on the oncology field.